These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27119092)

  • 21. Effects of oral or intravenous inoculation with Brucella abortus strain RB51 vaccine in beagles.
    Palmer MV; Cheville NF
    Am J Vet Res; 1997 Aug; 58(8):851-6. PubMed ID: 9256969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bovine coronavirus in naturally and experimentally exposed calves; viral shedding and the potential for transmission.
    Oma VS; Tråvén M; Alenius S; Myrmel M; Stokstad M
    Virol J; 2016 Jun; 13():100. PubMed ID: 27296861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas.
    Omar NB; Bentley RT; Crossman DK; Foote JB; Koehler JW; Markert JM; Platt SR; Rissi DR; Shores A; Sorjonen D; Yanke AB; Gillespie GY; Chambers MR
    Neurosurg Focus; 2021 Feb; 50(2):E5. PubMed ID: 33524948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of Vaccinia Virus in Milk: Evidence of a Systemic and Persistent Infection in Experimentally Infected Cows.
    de Oliveira TM; Guedes MI; Rehfeld IS; Matos AC; Rivetti AV; Alves PA; Galinari GC; Cerqueira MM; Abrahão JS; Lobato ZI
    Foodborne Pathog Dis; 2015 Nov; 12(11):898-903. PubMed ID: 26545169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-cell-passage canine coronavirus vaccine providing sterilising immunity.
    Pratelli A
    J Small Anim Pract; 2007 Oct; 48(10):574-8. PubMed ID: 17877547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent.
    Gentschev I; Stritzker J; Hofmann E; Weibel S; Yu YA; Chen N; Zhang Q; Bullerdiek J; Nolte I; Szalay AA
    Cancer Gene Ther; 2009 Apr; 16(4):320-8. PubMed ID: 18949014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
    Afolabi MO; Ishola D; Manno D; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Greenwood B; Leyssen M; Douoguih M; Leigh B; Watson-Jones D;
    Lancet Infect Dis; 2022 Jan; 22(1):110-122. PubMed ID: 34529962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
    Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
    Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of Crimean-Congo hemorrhagic fever virus genome in saliva and urine.
    Bodur H; Akinci E; Ongürü P; Carhan A; Uyar Y; Tanrici A; Cataloluk O; Kubar A
    Int J Infect Dis; 2010 Mar; 14(3):e247-9. PubMed ID: 19656706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential biodistribution of oncolytic poxvirus administered systemically in an autochthonous model of hepatocellular carcinoma.
    Baril P; Touchefeu Y; Cany J; Cherel Y; Thorne SH; Tran L; Conchon S; Vassaux G
    J Gene Med; 2011 Dec; 13(12):692-701. PubMed ID: 22028274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism.
    Foloppe J; Kempf J; Futin N; Kintz J; Cordier P; Pichon C; Findeli A; Vorburger F; Quemeneur E; Erbs P
    Mol Ther Oncolytics; 2019 Sep; 14():1-14. PubMed ID: 31011628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antigen profiling analysis of vaccinia virus injected canine tumors: oncolytic virus efficiency predicted by boolean models.
    Cecil A; Gentschev I; Adelfinger M; Nolte I; Dandekar T; Szalay AA
    Bioengineered; 2014; 5(5):319-25. PubMed ID: 25482233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-time reverse transcription polymerase chain reaction method for detection of Canine distemper virus modified live vaccine shedding for differentiation from infection with wild-type strains.
    Wilkes RP; Sanchez E; Riley MC; Kennedy MA
    J Vet Diagn Invest; 2014 Jan; 26(1):27-34. PubMed ID: 24532693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic cellular viroimmunotherapy for canine high-grade gliomas.
    Cloquell A; Mateo I; Gambera S; Pumarola M; Alemany R; García-Castro J; Perisé-Barrios AJ
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors.
    Béguin J; Laloy E; Cochin S; Gantzer M; Farine I; Pichon C; Moreau B; Foloppe J; Balloul JM; Machon C; Guitton J; Tierny D; Klonjkowski B; Quéméneur E; Maurey C; Erbs P
    Mol Ther Oncolytics; 2023 Sep; 30():103-116. PubMed ID: 37635744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraepithelial DNA immunisation with a plasmid encoding a codon optimised COPV E1 gene sequence, but not the wild-type gene sequence completely protects against mucosal challenge with infectious COPV in beagles.
    Moore RA; Santos EB; Nicholls PK; White KL; Anderson DM; Lloyd A; Topley P; Romanos M; Thomsen L; Parmar V; Walcott S; Gough GW; Stanley MA
    Virology; 2002 Dec; 304(2):451-9. PubMed ID: 12504584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.
    Roth JC; Cassady KA; Cody JJ; Parker JN; Price KH; Coleman JM; Peggins JO; Noker PE; Powers NW; Grimes SD; Carroll SL; Gillespie GY; Whitley RJ; Markert JM
    Hum Gene Ther Clin Dev; 2014 Mar; 25(1):16-27. PubMed ID: 24649838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.
    Adelfinger M; Bessler S; Frentzen A; Cecil A; Langbein-Laugwitz J; Gentschev I; Szalay AA
    Viruses; 2015 Jul; 7(7):4075-92. PubMed ID: 26205404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.
    Evgin L; Acuna SA; Tanese de Souza C; Marguerie M; Lemay CG; Ilkow CS; Findlay CS; Falls T; Parato KA; Hanwell D; Goldstein A; Lopez R; Lafrance S; Breitbach CJ; Kirn D; Atkins H; Auer RC; Thurman JM; Stahl GL; Lambris JD; Bell JC; McCart JA
    Mol Ther; 2015 Jun; 23(6):1066-1076. PubMed ID: 25807289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JNK-deficiency enhanced oncolytic vaccinia virus replication and blocked activation of double-stranded RNA-dependent protein kinase.
    Hu W; Hofstetter W; Guo W; Li H; Pataer A; Peng HH; Guo ZS; Bartlett DL; Lin A; Swisher SG; Fang B
    Cancer Gene Ther; 2008 Sep; 15(9):616-24. PubMed ID: 18535619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.